Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

Root Cause Analysis - NAPLEX

  1. A 45-year-old female (70 kg) presents with severe muscle pain and weakness for 3 days. Medical history includes hyperlipidemia and GERD; allergies: none. Current medications: simvastatin 40 mg PO nightly (stable for 1 year), omeprazole 20 mg PO daily, and clarithromycin 500 mg PO BID (started 5 days ago for sinusitis). Labs: CK 5,200 U/L (high; normal <200), SCr 1.8 mg/dL (baseline 0.9), AST 120 U/L (high), ALT 98 U/L (high); no recent hospitalizations. What is the most likely cause of this patient's symptoms?
    Answer: Clarithromycin increases simvastatin exposure via CYP3A4 inhibition, leading to statin-associated rhabdomyolysis This question tests root cause analysis of statin-induced rhabdomyolysis due to a significant CYP3A4-mediated drug interaction. The key patient-specific factor is the recent addition of clarithromycin, a strong CYP3A4 inhibitor, to a patient taking simvastatin, which is extensively metabolized by CYP3A4. The correct answer (A) identifies that clarithromycin inhibits simvastatin metabolism, leading to dramatically increased statin exposure and rhabdomyolysis, evidenced by markedly elevated CK (5,200 U/L), acute kidney injury, and transaminitis. Option B is incorrect because omeprazole does not significantly affect simvastatin absorption or metabolism. Option C is incorrect as simvastatin does not cause bacterial infections. Option D is incorrect because clarithromycin alone rarely causes rhabdomyolysis without the interaction. The clinical pearl is that simvastatin and lovastatin have the highest risk for CYP3A4 interactions among statins, with FDA recommending avoiding simvastatin doses >20 mg daily with CYP3A4 inhibitors or using alternative statins like rosuvastatin or pravastatin that are not CYP3A4 substrates.
  2. A 29-year-old man (78 kg) with HIV has a detectable viral load after being undetectable for years. Current medications: bictegravir/emtricitabine/tenofovir alafenamide 1 tablet PO daily, multivitamin with minerals daily (new in last 2 months), and calcium carbonate 500 mg chewable tablets PRN heartburn (using several daily); he often takes all morning medications together. Labs: HIV RNA 8,500 copies/mL (previously undetectable), SCr 1.0 mg/dL; allergies: none; PMH: HIV, GERD; no recent hospitalizations. Which factor is contributing to the therapeutic failure?
    Answer: Chelation interaction from polyvalent cations reducing integrase inhibitor absorption when taken together This question tests root cause analysis in absorption interactions affecting HIV therapy efficacy. The key patient-specific factor is coadministration of bictegravir with polyvalent cations from supplements, chelating the drug. Choice A correctly identifies the root cause as reduced absorption leading to virologic failure. Choice B is incorrect as tenofovir does not induce CYP, and choice C is suboptimal because multivitamins do not cause immune syndrome. Choice D is wrong as calcium affects integrase inhibitors, not emtricitabine. A pearl is to separate dosing by 2 hours. Evidence-based adherence counseling prevents failure.
  3. A 58-year-old woman (70 kg) comes to the pharmacy with severe muscle pain and dark urine that began 1 week after a medication change. Current medications: simvastatin 40 mg PO nightly (increased from 20 mg 10 days ago), amlodipine 10 mg PO daily, metformin 1000 mg PO twice daily, and omeprazole 20 mg PO daily; no OTC/herbals. Labs from urgent care: CK 5,800 U/L (elevated), SCr 1.9 mg/dL (baseline 0.9), AST 98 U/L (elevated); allergies: none; PMH: T2DM, HTN, hyperlipidemia; no recent hospitalizations. What is the primary reason for the adverse drug reaction?
    Answer: Amlodipine increasing simvastatin exposure leading to statin-associated rhabdomyolysis risk This question tests root cause analysis in recognizing drug interactions contributing to statin toxicity and rhabdomyolysis. The key patient-specific factor is the recent increase in simvastatin dose while on amlodipine, exacerbating muscle injury risk. Choice A correctly identifies the root cause as amlodipine inhibiting CYP3A4, increasing simvastatin exposure and leading to elevated CK and AKI. Choice B is incorrect because metformin does not cause rhabdomyolysis, and choice C is suboptimal as omeprazole does not significantly reduce statin absorption. Choice D is wrong as diabetes progression alone does not explain acute myositis with lab abnormalities. A clinical pearl is to always assess for CYP inhibitors when escalating statin doses, using dose limits like simvastatin 20 mg with amlodipine. Evidence-based decision-making requires correlating symptoms with labs and medication timelines for prompt intervention.
  4. A 38-year-old male (76 kg) with epilepsy presents after a breakthrough generalized tonic-clonic seizure. Medical history: focal epilepsy well-controlled for years; allergy: none. Current medications: lamotrigine 200 mg PO BID (stable), valproic acid 500 mg PO BID (started 3 weeks ago by a new provider), and sertraline 50 mg PO daily; he was hospitalized last month for depression and medication reconciliation was incomplete. Labs: lamotrigine level not available, valproic acid level 78 mcg/mL (therapeutic), AST/ALT mildly elevated; he reports new dizziness and blurred vision since starting valproic acid. Which action should the pharmacist take to prevent recurrence?
    Answer: Identify the interaction where valproic acid increases lamotrigine exposure and coordinate dose adjustment and monitoring This question tests root cause analysis of breakthrough seizures due to incomplete medication reconciliation and a significant antiepileptic drug interaction. The key patient-specific factor is the addition of valproic acid to stable lamotrigine therapy without appropriate dose adjustment, where valproic acid inhibits lamotrigine glucuronidation, approximately doubling its half-life and exposure. The correct answer (B) identifies the need to recognize this interaction and coordinate dose reduction of lamotrigine (typically by 50%) with close monitoring for both efficacy and toxicity. Option A is incorrect because valproic acid increases, not decreases, lamotrigine concentrations. Option C is incorrect as sertraline rarely affects seizure control at therapeutic doses. Option D is incorrect because lamotrigine absorption is not significantly affected by food, and this wouldn't address the underlying interaction. The clinical pearl is that medication reconciliation failures during care transitions are a leading cause of preventable adverse events, and pharmacists play a crucial role in identifying and managing complex drug interactions, particularly with narrow therapeutic index medications like antiepileptics.
  5. A 45-year-old man (85 kg) with GERD reports that his once-daily omeprazole "stopped working" after he began a new medication for tuberculosis 3 weeks ago. Current medications: omeprazole 20 mg PO daily, rifampin 600 mg PO daily (new), isoniazid 300 mg PO daily, pyrazinamide 1500 mg PO daily, and ethambutol 1200 mg PO daily; he is adherent. Labs: AST 62 U/L (high), ALT 70 U/L (high), SCr 0.9 mg/dL; allergies: none; PMH: GERD; recent intervention: started RIPE therapy. Which factor is contributing to the therapeutic failure?
    Answer: Rifampin enzyme induction increasing omeprazole metabolism leading to reduced acid suppression This question tests root cause analysis in pharmacy practice by identifying the underlying reason for therapeutic failure of omeprazole in a patient with GERD after initiating tuberculosis treatment. The key patient-specific factor is the recent addition of rifampin, a potent enzyme inducer, to the patient's regimen, which coincides with the onset of reduced omeprazole efficacy. The correct answer, rifampin enzyme induction increasing omeprazole metabolism leading to reduced acid suppression, identifies the root cause because rifampin induces CYP2C19 and CYP3A4 enzymes, accelerating omeprazole breakdown and diminishing its proton pump inhibitory effects, thereby addressing the need for potential dose adjustment or alternative therapy. Isoniazid as a distractor is incorrect because it primarily inhibits rather than induces CYP2C19, which would typically increase rather than decrease omeprazole levels, representing a common misconception about antitubercular drug interactions. Pyrazinamide and ethambutol are suboptimal choices as they do not significantly affect gastric acid suppression or cause esophagitis in this context, often misleading due to assumptions about direct gastrointestinal side effects without pharmacokinetic evidence. A transferable clinical pearl is to systematically review medication timelines and pharmacokinetic profiles during root cause analysis to pinpoint drug interactions as the etiology of therapeutic failures. Emphasizing thorough investigation, such as consulting interaction databases and monitoring drug levels when feasible, ensures evidence-based decision-making and prevents recurrence in pharmacy practice.
  6. A 63-year-old female (60 kg) with COPD presents to urgent care with tremor, palpitations, and insomnia for 1 week. Medical history: COPD, osteoporosis, and anxiety; allergy: aspirin (bronchospasm). Current medications: albuterol HFA 2 puffs every 4–6 hours PRN, tiotropium Respimat 2 inhalations daily, fluticasone/salmeterol 250/50 one inhalation BID, and a new prescription for albuterol nebulizer solution 2.5 mg every 4 hours PRN (added 10 days ago after a COPD flare treated with prednisone). Vitals: HR 112 bpm, BP 146/88; labs: K 3.2 mEq/L (low), SCr 0.8 mg/dL, AST/ALT WNL; no hospitalization. Which medication change is most likely responsible for the patient's new symptoms?
    Answer: Adding frequent albuterol nebulizer use on top of albuterol inhaler leading to excessive beta-2 agonist effects This question tests root cause analysis of beta-agonist toxicity from additive therapy in COPD management. The key patient-specific factor is the addition of scheduled albuterol nebulizer treatments to a regimen already containing both short-acting (albuterol HFA) and long-acting (salmeterol) beta-agonists. The correct answer (B) identifies that frequent albuterol nebulizer use on top of existing beta-agonist therapy led to excessive beta-2 stimulation, causing classic toxicity symptoms including tremor, tachycardia (HR 112), hypertension, hypokalemia (K 3.2), and insomnia. Option A is incorrect because tiotropium is an anticholinergic that doesn't cause beta-agonist toxicity. Option C is incorrect as fluticasone/salmeterol doesn't cause opioid withdrawal. Option D is incorrect because completed prednisone courses don't cause persistent adrenal crisis 10 days later. The clinical pearl is that beta-agonist effects are additive across all formulations, and patients on LABA therapy should use SABA rescue medications judiciously, with careful monitoring for signs of excessive beta-stimulation including electrolyte abnormalities.
  7. A 72-year-old man (82 kg) presents to the ED with confusion and unsteady gait 3 days after discharge for pneumonia; his wife reports he has been "very sleepy" since starting a new antibiotic. Current medications: warfarin 5 mg PO daily (stable for months), metoprolol succinate 50 mg PO daily, sertraline 50 mg PO daily, and trimethoprim-sulfamethoxazole DS 1 tablet PO twice daily started 4 days ago; no recent warfarin dose change. Labs: INR 6.8 (goal 2–3), Hgb 12.9 g/dL, SCr 1.0 mg/dL, AST/ALT WNL; allergy: penicillin (rash); PMH: atrial fibrillation, HTN. Which medication change is most likely responsible for the patient's new symptoms?
    Answer: Trimethoprim-sulfamethoxazole increasing warfarin effect via CYP2C9 inhibition This question tests root cause analysis in identifying drug interactions leading to adverse effects in anticoagulation therapy. The key patient-specific factor is the recent initiation of trimethoprim-sulfamethoxazole in a patient stable on warfarin, resulting in supratherapeutic INR and associated symptoms. Choice B correctly identifies the root cause as trimethoprim-sulfamethoxazole inhibiting CYP2C9, increasing warfarin's anticoagulant effect, which explains the elevated INR and potential for bleeding-related confusion and gait instability. Choice A is incorrect because sertraline's side effects are not typically dose-related ataxia in this context, and choice C is suboptimal as metoprolol clearance is hepatic, not renal, with normal SCr. Choice D is wrong as there was no underdosing, and INR is elevated, not subtherapeutic. A useful framework for root cause analysis involves reviewing recent medication changes and checking for pharmacokinetic interactions using tools like drug interaction databases. Thorough investigation, including lab monitoring and patient history, ensures evidence-based adjustments to prevent recurrence.
  8. A 40-year-old woman (62 kg) with asthma reports worsening control and increased nighttime symptoms over the last month. Current medications: budesonide/formoterol 160/4.5 two inhalations twice daily, albuterol HFA PRN, and a new propranolol 40 mg PO twice daily started 4 weeks ago for performance anxiety; she is adherent to inhalers. Vitals: HR 58 bpm, wheezing on exam; labs: none; allergies: none; PMH: asthma. Which medication change is most likely responsible for the patient's new symptoms?
    Answer: Propranolol antagonizing beta-2 receptors leading to bronchospasm and reduced bronchodilator response This question tests root cause analysis in beta-blockers exacerbating respiratory conditions. The key patient-specific factor is initiating non-selective propranolol in an asthma patient, blocking beta-2 receptors. Choice A correctly identifies the root cause as bronchospasm reducing asthma control. Choice B is incorrect as formoterol does not cause paradoxical effects routinely, and choice C is suboptimal because budesonide hypersensitivity is rare. Choice D is wrong as albuterol overuse takes longer for remodeling. A framework assesses selectivity in beta-blockers for asthmatics. Thorough review optimizes evidence-based therapy.
  9. A 55-year-old man (92 kg) with hypertension presents with persistent cough and facial swelling that began within hours of taking his first dose of lisinopril. Current medications: lisinopril 10 mg PO daily (new today), amlodipine 5 mg PO daily, and atorvastatin 20 mg PO nightly; vitals: BP 148/86 mmHg; labs: SCr 0.9 mg/dL, K 4.3 mEq/L; allergies: none; PMH: HTN, hyperlipidemia; no recent hospitalizations. What is the most likely cause of this patient's symptoms?
    Answer: Bradykinin-mediated angioedema from ACE inhibitor initiation This question tests root cause analysis in rapid-onset adverse effects from ACE inhibitors. The key patient-specific factor is the first dose of lisinopril triggering bradykinin accumulation. Choice A correctly identifies the root cause as angioedema presenting as cough and swelling. Choice B is incorrect as anaphylaxis to atorvastatin is unlikely after long use, and choice C is suboptimal because amlodipine edema is peripheral and delayed. Choice D is wrong without adherence issues. A framework recognizes class effects in hypertensives. Thorough monitoring ensures evidence-based switching to ARBs.
  10. A 70-year-old female (68 kg) is seen in clinic for uncontrolled blood pressure and reports she "never misses" her medications. Medical history: hypertension, osteoarthritis, and CKD stage 2; allergy: none. Current medications: lisinopril 40 mg PO daily, amlodipine 10 mg PO daily, hydrochlorothiazide 25 mg PO daily (added 6 weeks ago), and ibuprofen 600 mg PO TID (started OTC 1 month ago for knee pain). Vitals: BP 168/94 mmHg; labs: SCr 1.4 mg/dL (baseline 1.0), K 5.3 mEq/L (high), BUN 34 mg/dL (high); no recent hospitalizations. Which factor is contributing to the therapeutic failure?
    Answer: Ibuprofen use causing reduced antihypertensive/diuretic effectiveness and worsening renal function This question tests root cause analysis of antihypertensive failure due to NSAID interference with multiple drug classes. The key patient-specific factor is the addition of high-dose ibuprofen (600 mg TID) to a regimen containing an ACE inhibitor, diuretic, and baseline CKD. The correct answer (A) identifies that NSAIDs reduce the effectiveness of ACE inhibitors and diuretics through prostaglandin inhibition, while also worsening renal function (SCr increased from 1.0 to 1.4) and causing hyperkalemia (K 5.3) through reduced renal potassium excretion. Option B is incorrect because hydrochlorothiazide works within days to weeks, not months. Option C is incorrect as amlodipine causes hypokalemia, not hyperkalemia, and doesn't prevent ACE inhibitor efficacy. Option D is incorrect because ACE inhibitors work independently of potassium supplementation. The clinical pearl is that NSAIDs antagonize most antihypertensive drug classes except calcium channel blockers, with particular risk in elderly patients with CKD, often requiring alternative pain management strategies like acetaminophen or topical agents.
  11. A 67-year-old man (84 kg) with gout presents with severe fatigue and mouth sores 3 weeks after starting a new medication. Current medications: allopurinol 300 mg PO daily (stable), azathioprine 150 mg PO daily (started 3 weeks ago for inflammatory bowel disease), lisinopril 20 mg PO daily; labs: WBC 1.2 x103x10^3/µL (low), ANC 400/µL (low), Hgb 9.8 g/dL (low), platelets 85 x103x10^3/µL (low), SCr 1.0 mg/dL; allergies: none; PMH: gout, IBD. What is the primary reason for the adverse drug reaction?
    Answer: Allopurinol inhibition of xanthine oxidase increasing azathioprine/6-MP levels causing myelosuppression This question tests root cause analysis in pharmacokinetic interactions enhancing immunosuppressant toxicity. The key patient-specific factor is starting azathioprine without adjusting for allopurinol's xanthine oxidase inhibition. Choice A correctly identifies the root cause as increased 6-MP levels causing myelosuppression. Choice B is incorrect as lisinopril rarely causes aplastic anemia, and choice C is suboptimal because allopurinol does not deplete folate. Choice D is wrong as azathioprine is not underdosed. A pearl is to reduce azathioprine dose by 75% with allopurinol. Evidence-based monitoring prevents severe ADRs.
  12. A 61-year-old male (90 kg) with gout presents with severe bilateral ankle pain and swelling despite starting allopurinol 2 weeks ago. Medical history: gout, hypertension, and type 2 diabetes; allergy: none. Current medications: allopurinol 300 mg PO daily (new), hydrochlorothiazide 25 mg PO daily, losartan 50 mg PO daily, metformin 1,000 mg PO BID, and he stopped taking colchicine 0.6 mg PO daily last month because it "upset his stomach." Labs: uric acid 6.2 mg/dL (down from 9.5), SCr 1.0 mg/dL, AST/ALT WNL; no recent hospitalizations. What is the most likely cause of this patient's symptoms?
    Answer: Initiation of urate-lowering therapy without anti-inflammatory prophylaxis leading to early gout flares This question tests root cause analysis of paradoxical gout flares during initiation of urate-lowering therapy. The key patient-specific factor is starting allopurinol without concurrent anti-inflammatory prophylaxis, after the patient discontinued colchicine due to GI intolerance. The correct answer (B) identifies that initiating urate-lowering therapy causes rapid changes in serum uric acid levels, which can mobilize tissue deposits and paradoxically trigger acute flares in the first few months of treatment, despite improving uric acid levels (6.2 mg/dL). Option A is incorrect because gout flares commonly occur during early treatment even when uric acid reaches goal. Option C is incorrect as losartan actually has mild uricosuric effects and doesn't worsen gout. Option D is incorrect because metformin doesn't precipitate urate crystals or trigger gout. The clinical pearl is that anti-inflammatory prophylaxis (colchicine, NSAIDs, or low-dose corticosteroids) should be continued for 3-6 months when initiating urate-lowering therapy, with alternatives like low-dose NSAIDs or corticosteroids available for colchicine-intolerant patients.
  13. A 66-year-old male (84 kg) with a mechanical aortic valve on chronic warfarin presents with epistaxis and dark stools for 1 day. Medications: warfarin 5 mg PO daily (stable for months), amiodarone 200 mg PO daily, atorvastatin 40 mg PO nightly, and acetaminophen PRN; he started trimethoprim-sulfamethoxazole DS 1 tablet PO BID yesterday for cellulitis from an urgent care visit. Labs: INR 6.8 (high; goal 2.5–3.5), Hgb 10.2 g/dL (baseline 13), SCr 1.1 mg/dL, AST/ALT WNL; allergy: none; no recent hospitalizations. What is the primary reason for the adverse drug reaction?
    Answer: Trimethoprim-sulfamethoxazole inhibits warfarin metabolism, increasing INR and bleeding risk This question tests root cause analysis of a significant drug-drug interaction causing supratherapeutic INR and bleeding. The key patient-specific factor is the recent initiation of trimethoprim-sulfamethoxazole for cellulitis, which is a potent inhibitor of CYP2C9, the primary enzyme responsible for warfarin metabolism. The correct answer (B) identifies that trimethoprim-sulfamethoxazole inhibits warfarin metabolism, leading to accumulation, elevated INR (6.8), and bleeding manifestations including epistaxis and melena. Option A is incorrect because amiodarone inhibits (not induces) warfarin metabolism, but this interaction would have stabilized given chronic concurrent use. Option C is incorrect as atorvastatin does not chelate warfarin or significantly affect its pharmacokinetics. Option D is incorrect because while high-dose acetaminophen can enhance warfarin's effect, PRN use is unlikely to cause GI bleeding independent of anticoagulation. The clinical pearl is that trimethoprim-sulfamethoxazole is one of the highest-risk antibiotics for warfarin interactions, often requiring empiric warfarin dose reduction of 25-50% and close INR monitoring when co-prescribed.
  14. A 62-year-old man (86 kg) with benign prostatic hyperplasia reports lightheadedness and one episode of syncope after starting a new medication for erectile dysfunction. Current medications: tamsulosin 0.4 mg PO nightly (stable), sildenafil 100 mg PO as needed (new; took 1 hour before symptoms), hydrochlorothiazide 25 mg PO daily; BP in pharmacy: 88/54 mmHg; labs: none; allergies: none; PMH: BPH, HTN. What is the most likely cause of this patient's symptoms?
    Answer: Additive vasodilation and hypotension from concurrent PDE5 inhibitor and alpha-1 blocker use This question tests root cause analysis in vasodilator interactions causing hypotension. The key patient-specific factor is combining sildenafil with tamsulosin, amplifying vasodilation. Choice A correctly identifies the root cause as additive effects leading to syncope. Choice B is incorrect as hydrochlorothiazide does not cause hypoglycemia, and choice C is suboptimal because tamsulosin does not cause hypertension. Choice D is wrong as sildenafil lacks beta-blockade. A pearl is to limit sildenafil to 25 mg with alpha-blockers. Thorough counseling supports evidence-based use.
  15. A 50-year-old woman (73 kg) with rheumatoid arthritis presents with fever, sore throat, and malaise 1 month after starting methotrexate. Current medications: methotrexate 15 mg PO weekly (started 4 weeks ago), folic acid 1 mg PO daily, trimethoprim-sulfamethoxazole DS 1 tablet PO daily (started 2 weeks ago for UTI prophylaxis by another provider), and prednisone 5 mg PO daily; labs: WBC 2.0 x103x10^3/µL (low), platelets 110 x103x10^3/µL (low), SCr 1.1 mg/dL; allergies: none; PMH: RA; recent hospitalization: none. What is the primary reason for the adverse drug reaction?
    Answer: Additive antifolate effects from trimethoprim-sulfamethoxazole with methotrexate increasing myelosuppression risk This question tests root cause analysis in antifolate interactions enhancing immunosuppressant toxicity. The key patient-specific factor is adding trimethoprim-sulfamethoxazole to methotrexate, increasing myelosuppression. Choice A correctly identifies the root cause as additive effects causing cytopenias. Choice B is incorrect as folic acid mitigates toxicity, and choice C is suboptimal because prednisone does not cause neutropenia. Choice D is wrong as methotrexate is weekly for RA. A framework avoids antifolates in methotrexate users. Evidence-based monitoring prevents ADRs.
  16. A 48-year-old man (80 kg) with epilepsy presents with dizziness, nystagmus, and slurred speech 5 days after starting an antibiotic for sinusitis. Current medications: phenytoin 300 mg PO nightly (stable), amoxicillin/clavulanate 875/125 mg PO twice daily (new), and famotidine 20 mg PO twice daily; labs: total phenytoin 28 mcg/mL (high; therapeutic 10–20), albumin 4.0 g/dL, SCr 0.8 mg/dL; allergies: none; PMH: epilepsy. What is the most likely cause of this patient's symptoms?
    Answer: Phenytoin toxicity due to antibiotic-related alteration of metabolism or protein binding leading to elevated levels This question tests root cause analysis in antibiotic interactions elevating anticonvulsant levels. The key patient-specific factor is amoxicillin/clavulanate displacing phenytoin from protein binding. Choice A correctly identifies the root cause as toxicity from high phenytoin levels causing neurologic symptoms. Choice B is incorrect as amoxicillin/clavulanate does not cause cerebellar toxicity, and choice C is suboptimal because famotidine does not affect absorption. Choice D is wrong as sinusitis does not cause these deficits. A framework monitors levels post-antibiotic start. Evidence-based adjustments prevent toxicity.
  17. A 24-year-old woman (52 kg) presents to urgent care with tremor, palpitations, and insomnia that started after she began an OTC product for weight loss. Current medications: levothyroxine 88 mcg PO daily (stable), ethinyl estradiol/levonorgestrel 1 tablet PO daily, and a new OTC "energy/weight loss" supplement containing high-dose caffeine and yohimbine; no recent prescription changes. Labs: TSH 2.1 mIU/L (WNL), HR 118 bpm; allergies: none; PMH: hypothyroidism; no hospitalizations. What is the most likely cause of this patient's symptoms?
    Answer: Stimulant adverse effects from the OTC supplement causing sympathetic activation This question tests root cause analysis in distinguishing medication adverse effects from underlying conditions in symptomatic patients. The key patient-specific factor is the initiation of an OTC supplement containing stimulants like caffeine and yohimbine, mimicking hyperthyroidism symptoms. Choice B correctly identifies the root cause as stimulant-induced sympathetic activation, explaining tachycardia and insomnia with normal TSH. Choice A is incorrect as levothyroxine dose is stable without overdose signs, and choice C is suboptimal because oral contraceptives increase binding proteins but not free T4 toxicity. Choice D is wrong as allergies to levothyroxine are rare and not acute. A clinical pearl is to inquire about OTC products in root cause analysis, using timelines to correlate symptom onset. Evidence-based decision-making involves lab confirmation to rule out endogenous causes.
  18. A 79-year-old woman (55 kg) is brought to the ED for dizziness and a fall 1 week after a medication was added for overactive bladder. Current medications: oxybutynin ER 10 mg PO daily (started 7 days ago), diphenhydramine 25 mg PO nightly PRN sleep (used most nights), hydrochlorothiazide 25 mg PO daily, and donepezil 10 mg PO nightly; labs: Na 132 mEq/L (low), SCr 1.1 mg/dL; allergies: none; PMH: mild dementia, urinary incontinence, HTN; no recent hospitalizations. What is the most likely cause of this patient's symptoms?
    Answer: Additive anticholinergic effects from oxybutynin and diphenhydramine causing dizziness and falls This question tests root cause analysis in identifying cumulative anticholinergic effects in elderly patients with falls. The key patient-specific factor is the addition of oxybutynin alongside chronic diphenhydramine use, amplifying CNS side effects. Choice A correctly identifies the root cause as additive anticholinergic burden causing dizziness and orthostasis. Choice B is incorrect because donepezil is cholinergic, not anticholinergic, and choice C is suboptimal as hydrochlorothiazide causes hyponatremia, not hypernatremia. Choice D is wrong as allergies typically present differently. A clinical pearl is to use tools like the Beers Criteria to assess anticholinergic load in geriatrics. Evidence-based deprescribing relies on thorough medication reconciliation.
  19. A 29-year-old female (64 kg) presents to the pharmacy reporting persistent vaginal itching and thick discharge despite using fluconazole. Medical history: recurrent vulvovaginal candidiasis; allergy: none; not pregnant. Medications: fluconazole 150 mg PO once (taken 3 days ago), combined oral contraceptive daily, and she recently started rifampin 600 mg PO daily 2 weeks ago for latent tuberculosis infection. Labs: AST/ALT WNL, SCr 0.7 mg/dL; no recent hospitalizations. Which factor is contributing to the therapeutic failure?
    Answer: Rifampin induces metabolism of fluconazole, decreasing antifungal exposure and efficacy This question tests root cause analysis of antifungal treatment failure due to a significant drug interaction affecting fluconazole efficacy. The key patient-specific factor is the concurrent use of rifampin, a potent enzyme inducer that increases the metabolism of many drugs including fluconazole. The correct answer (A) identifies that rifampin induces CYP450 enzymes responsible for fluconazole metabolism, significantly reducing antifungal exposure and therapeutic efficacy, explaining persistent symptoms despite treatment. Option B is incorrect because oral contraceptives do not chelate or inactivate fluconazole. Option C is incorrect as fluconazole is highly effective for most Candida species causing vulvovaginal candidiasis. Option D is incorrect because single-dose fluconazole is effective without probiotics, though they may provide adjunctive benefit. The clinical pearl is that rifampin is one of the most potent enzyme inducers in clinical use, requiring dose adjustments or alternative agents for many concurrent medications, with effects persisting for weeks after discontinuation due to enzyme auto-induction.
  20. A 61-year-old man (76 kg) with a mechanical aortic valve presents with gum bleeding and nosebleeds. Current medications: warfarin 7.5 mg PO daily, amiodarone 200 mg PO daily (started 2 weeks ago for atrial fibrillation), atorvastatin 20 mg PO nightly, and levothyroxine 100 mcg PO daily; no warfarin dose adjustment was made when amiodarone was started. Labs: INR 5.9 (goal 2.5–3.5), AST/ALT WNL, SCr 1.0 mg/dL; allergies: none; recent hospitalization: cardioversion 2 weeks ago. Which medication change is most likely responsible for the patient's new symptoms?
    Answer: Amiodarone increasing warfarin exposure via CYP inhibition without warfarin dose reduction This question tests root cause analysis in detecting unadjusted anticoagulation amid interacting medications. The key patient-specific factor is starting amiodarone without reducing warfarin dose, potentiating anticoagulation. Choice B correctly identifies the root cause as CYP inhibition increasing warfarin exposure and INR, causing bleeding. Choice A is incorrect as atorvastatin does not reduce warfarin absorption, and choice C is suboptimal because levothyroxine stabilizes INR. Choice D is wrong without valve evidence. A framework involves anticipating interactions with narrow therapeutic index drugs. Thorough lab review supports evidence-based dose adjustments.

Start this quiz